Filing Flows › Teleflex (TFX) › Q2 2026 › vs Q1 2026
Teleflex (TFX) Q2 2026 vs Q1 2026 (quarter over quarter)
Teleflex's revenue rose $22.1M (+4%) from $548M in Q1 2026 to $570M in Q2 2026. The biggest changes: Vascular +$9.5M (+4%); Interventional +$7.2M (+4%); Surgical +$5.3M (+5%). Gross margin 58.2% against 56.1% (+2.1 pts).
Teleflex, Q2 2026: revenue $570M (+29% year over year), operating margin 12.8%, net earnings $99.7M, operating cash flow $91.9M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 58.2% | 56.1% | +2.1 pts |
| Operating margin | 12.8% | 3.7% | +9.1 pts |
| Net margin | 17.5% | -1.5% | +19.0 pts |
| Free cash flow margin | 13.7% | 5.1% | +8.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Vascular | $246M | $237M | $9.5M | +4% |
| Interventional | $212M | $205M | $7.2M | +4% |
| Surgical | $112M | $107M | $5.3M | +5% |
| Revenue | $570M | $548M | $22.1M | +4% |
| Gross profit | $332M | $307M | $24.3M | +8% |
| Cost of revenue | $239M | $241M | −$2.2M | -0.9% |
| Other income, net | $30.2M | −$27.3M | $57.6M | — |
| Operating profit | $72.8M | $20.2M | $52.6M | +261% |
| Operating expenses | $259M | $287M | −$28.4M | -10% |
| Pre-tax earnings | $103M | −$7.1M | $110M | — |
| Research & development | $45.1M | $44.4M | $736K | +2% |
| SG&A | $214M | $226M | −$12.5M | -6% |
| Net earnings | $99.7M | −$8.2M | $108M | — |
| Income tax | $3.4M | $1.0M | $2.4M | +234% |
| Depreciation & amortization | $49.8M | $53.7M | −$3.9M | -7% |
| Share-based compensation | $5.4M | $6.7M | −$1.3M | -19% |
| Working capital & other | $63.1M | $5.7M | $57.4M | 11× |
| Operating cash flow | $91.9M | $46.7M | $45.2M | +97% |
| Free cash flow (OCF − capex) | $77.9M | $27.9M | $50.0M | +179% |
| Capital expenditures | $14.0M | $18.8M | −$4.8M | -25% |
Questions
How much did Teleflex's revenue grow quarter over quarter in Q2 2026?
Teleflex's revenue rose $22.1M (+4%) from $548M in Q1 2026 to $570M in Q2 2026.
What drove Teleflex's revenue change in Q2 2026?
Vascular +$9.5M (+4%); Interventional +$7.2M (+4%); Surgical +$5.3M (+5%).